440 related articles for article (PubMed ID: 26626991)
1. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.
Uchida N; Sambe T; Yoneyama K; Fukazawa N; Kawanishi T; Kobayashi S; Shima M
Blood; 2016 Mar; 127(13):1633-41. PubMed ID: 26626991
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody mimicking factor VIII.
Nogami K
Thromb Res; 2016 May; 141 Suppl 2():S34-5. PubMed ID: 27207420
[TBL] [Abstract][Full Text] [Related]
3. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects.
Li H; Zhang W; Petry C; Li L; Fernandez E; Kiialainen A; Feng S; Hsu W; Li L; Wei Y; Schmitt C
Clin Pharmacol Drug Dev; 2021 Jan; 10(1):30-38. PubMed ID: 32433829
[TBL] [Abstract][Full Text] [Related]
5. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.
Muto A; Yoshihashi K; Takeda M; Kitazawa T; Soeda T; Igawa T; Sampei Z; Kuramochi T; Sakamoto A; Haraya K; Adachi K; Kawabe Y; Nogami K; Shima M; Hattori K
Blood; 2014 Nov; 124(20):3165-71. PubMed ID: 25274508
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
[TBL] [Abstract][Full Text] [Related]
7. A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers.
Staton TL; Peng K; Owen R; Choy DF; Cabanski CR; Fong A; Brunstein F; Alatsis KR; Chen H
BMC Pulm Med; 2019 Jan; 19(1):5. PubMed ID: 30616547
[TBL] [Abstract][Full Text] [Related]
8. A new era of treatment for patients with haemophilia A?
Klamroth R
Hamostaseologie; 2017 Aug; 37(3):216-218. PubMed ID: 27885373
[TBL] [Abstract][Full Text] [Related]
9. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
10. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
[TBL] [Abstract][Full Text] [Related]
11. Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A.
Lippi G; Favaloro EJ
Adv Clin Chem; 2019; 88():151-167. PubMed ID: 30612605
[TBL] [Abstract][Full Text] [Related]
12. Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers.
Kotani N; Yoneyama K; Kawakami N; Shimuta T; Fukase H; Kawanishi T
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):702-712. PubMed ID: 30230257
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
[TBL] [Abstract][Full Text] [Related]
14. Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.
Sampei Z; Igawa T; Soeda T; Funaki M; Yoshihashi K; Kitazawa T; Muto A; Kojima T; Nakamura S; Hattori K
MAbs; 2015; 7(1):120-8. PubMed ID: 25524207
[TBL] [Abstract][Full Text] [Related]
15. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
[TBL] [Abstract][Full Text] [Related]
16. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.
Muto A; Yoshihashi K; Takeda M; Kitazawa T; Soeda T; Igawa T; Sakamoto Y; Haraya K; Kawabe Y; Shima M; Yoshioka A; Hattori K
J Thromb Haemost; 2014 Feb; 12(2):206-213. PubMed ID: 24735117
[TBL] [Abstract][Full Text] [Related]
17. Safety of recombinant coagulation factors in treating hemophilia.
Morfini M; Rapisarda CAP
Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
[TBL] [Abstract][Full Text] [Related]
18. A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.
Yoneyama K; Schmitt C; Kotani N; Levy GG; Kasai R; Iida S; Shima M; Kawanishi T
Clin Pharmacokinet; 2018 Sep; 57(9):1123-1134. PubMed ID: 29214439
[TBL] [Abstract][Full Text] [Related]
19. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.
Muto A; Yoshihashi K; Takeda M; Kitazawa T; Soeda T; Igawa T; Sakamoto Y; Haraya K; Kawabe Y; Shima M; Yoshioka A; Hattori K
J Thromb Haemost; 2014 Feb; 12(2):206-13. PubMed ID: 24738137
[TBL] [Abstract][Full Text] [Related]
20. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Lenting PJ; Denis CV; Christophe OD
Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
